Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
isoptin 40 mg
viatris as - verapamilhydroklorid - tablett, filmdrasjert - 40 mg
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
isoptin 80 mg
viatris as - verapamilhydroklorid - tablett, filmdrasjert - 80 mg
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
isoptin 120 mg
mylan healthcare norge as - verapamilhydroklorid - tablett, filmdrasjert - 120 mg
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
kabiven
fresenius kabi norge as - halden - soyaolje, renset / glukosemonohydrat / alanin / arginin / aspartinsyre / glutaminsyre / glysin / histidin / isoleucin / leucin / lysinhydroklorid / metionin / fenylalanin / prolin / serin / treonin / tryptofan / tyrosin / valin / kalsiumkloriddihydrat / natriumglyserofosfat / magnesiumsulfatheptahydrat / kaliumklorid / natriumacetattrihydrat - infusjonsvæske, emulsjon
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
kabiven perifer
fresenius kabi norge as - halden - soyaolje, renset / glukosemonohydrat / alanin / arginin / aspartinsyre / glutaminsyre / glysin / histidin / isoleucin / leucin / lysinhydroklorid / metionin / fenylalanin / prolin / serin / treonin / tryptofan / tyrosin / valin / kalsiumkloriddihydrat / natriumglyserofosfat / magnesiumsulfatheptahydrat / kaliumklorid / natriumacetattrihydrat - infusjonsvæske, emulsjon
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
ticovac 2.4 mikrog/ sprøyte
pfizer as - skogflåttencefalittvirus (tbe), inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 2.4 mikrog/ sprøyte
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
ticovac junior 1.2 mikrog/ sprøyte
pfizer as - skogflåttencefalittvirus (tbe), inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 1.2 mikrog/ sprøyte
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
willfact 1000 ie
lfb biomedicaments - von willebrandfaktor (human) - pulver og væske til injeksjonsvæske, oppløsning - 1000 ie
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
tolak 40 mg/ g
pierre fabre medicament - fluorouracil - krem - 40 mg/ g
Ευρωπαϊκή Ένωση -
Νορβηγικά -
EMA (European Medicines Agency)
sarclisa
sanofi winthrop industrie - isatuximab - multippelt myelom - antineoplastiske midler - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.